

## Product datasheet for **TL303600**

### **KSR2 Human shRNA Plasmid Kit (Locus ID 283455)**

#### **Product data:**

<b>Product Type:</b>	shRNA Plasmids
<b>Product Name:</b>	KSR2 Human shRNA Plasmid Kit (Locus ID 283455)
<b>Locus ID:</b>	283455
<b>Vector:</b>	pGFP-C-shLenti (TR30023)
<b>E. coli Selection:</b>	Chloramphenicol (34 ug/ml)
<b>Mammalian Cell Selection:</b>	Puromycin
<b>Format:</b>	Lentiviral plasmids
<b>Components:</b>	KSR2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 283455). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
<b>RefSeq:</b>	<a href="#">NM_173598</a> , <a href="#">NM_173598.1</a> , <a href="#">NM_173598.2</a> , <a href="#">NM_173598.3</a> , <a href="#">NM_173598.4</a> , <a href="#">BC107106</a> , <a href="#">BC107107</a> , <a href="#">BC127603</a>
<b>UniProt ID:</b>	<a href="#">Q6VAB6</a>
<b>Summary:</b>	Location-regulated scaffold connecting MEK to RAF. Has very low protein kinase activity and can phosphorylate MAP2K1 at several Ser and Thr residues with very low efficiency (in vitro). Interaction with BRAF enhances KSR2-mediated phosphorylation of MAP2K1 (in vitro). Blocks MAP3K8 kinase activity and MAP3K8-mediated signaling. Acts as a negative regulator of MAP3K3-mediated activation of ERK, JNK and NF-kappa-B pathways, inhibiting MAP3K3-mediated interleukin-8 production.[UniProtKB/Swiss-Prot Function]
<b>shRNA Design:</b>	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).